Healthcare Professionals | Full Prescribing Information | Glossary | Register | Unsubscribe
Glaucoma Medication: LUMIGAN About LUMIGAN® About LUMIGAN: Glaucoma Medication
Test
      Your Eyesight
      About LUMIGAN®
      Tools and Resources
  Full Prescribing Information
Home > About LUMIGAN References
References
About LUMIGAN: Glaucoma Medication
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.Arch Ophthalmol. 2002;120(10):1268-1279.

Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, Whitcup SM for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002 Oct;120(10):1286-93.

Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.

Sommer A, Katz J, Quigley HA, et al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991;109(1):77-83.

The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.

Noe G, Ferraro J, Lamoureux E, Rait J, Keeffe JE. Associations between glaucomatous visual field loss and participation in activities of daily living. Clin Experiment Ophthalmol. 2003 Dec;31(6):482-6.

Hoste AM. New insights into the subjective perception of visual field defects. Bull Soc Belge Ophtalmol. 2003;(287):65-71.

Nelson P, Aspinall P, Papasouliotis O, Worton B, O'Brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003 Apr;12(2):139-50.

Nelson P, Aspinall P, O'Brien C. Patients' perception of visual impairment in glaucoma: a pilot study. Br J Ophthalmol. 1999 May;83(5):546-52.

Butler RN, Faye EE, Guazzo E, Kupfer C. Keeping an eye on vision: primary care of age-related ocular disease. Part 1. Geriatrics. 1997 Aug;52(8):30-41.

Herndon JG, Helmick CG, Sattin RW, Stevens JA, DeVito C, Wingo PA. Chronic medical conditions and risk of fall injury events at home in older adults. J Am Geriatr Soc. 1997 Jun;45(6):739-43.

Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study J Am Geriatr Soc. 1998 Jan;46(1):58-64.

Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci. 2000;41(3):741-748.

Knudtson MD, Klein BE, Klein R, Cruickshanks KJ, Lee KE. Age-related eye disease, quality of life, and functional activity. Arch Ophthalmol. 2005 Jun;123(6):807-14.

Owsley C, McGwin G Jr, Ball K. Vision impairment, eye disease, and injurious motor vehicle crashes in the elderly. Ophthalmic Epidemiol. 1998 Jun;5(2):101-13.

Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982;100(1):135-146.

Szlyk JP, Mahler CL, Seiple W, Edward DP, Wilensky JT. Driving performance of glaucoma patients correlates with peripheral visual field loss. J Glaucoma. 2005 Apr;14(2):145-50.


 
   
 
 

LUMIGAN (bimatoprost ophthalmic solution) 0.03% is for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

Important Safety Information
LUMIGAN (bimatoprost ophthalmic solution) 0.03% has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN is used. After stopping LUMIGAN, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond 5 years are not known.

The most common side effects are eye redness,  growth of eyelashes,  and itchy eyes.

About LUMIGAN: Glaucoma Medication
  Privacy Policy Terms of Use
ALLERGAN
 
LUMIGAN® Footer
Full Prescribing Information Glossary Register